CDKN2D: A Potential Drug Target and Biomarker for cancer (G1032)

Target Name: CDKN2D

NCBI ID: G1032

CDKN2D

CDKN2D: A Potential Drug Target and Biomarker for cancer

Abstract:
CDKN2D is a gene that encodes for a protein known as p16INK4a. p16INK4a is a non-coding RNA gene that has been linked to various diseases, including cancer. CDKN2D is a variant of the p16INK4a gene that has unique functional characteristics. This article discusses the potential implications of CDKN2D as a drug target and biomarker for cancer.

Introduction:
Cancer is a leading cause of death worldwide, with over 38 million people succumbing to the disease. One of the major challenges in the fight against cancer is the development of resistance to traditional therapies. As cancer treatments become more effective, the cancer cells can evolve to evade the effects of those treatments. This process is known as \"resistance,\" and it is a major factor in the development and progression of cancer.

CDKN2D: A Potential Drug Target:

CDKN2D is a variant of the p16INK4a gene that has unique functional characteristics. The p16INK4a gene is a non-coding RNA gene that has been linked to various diseases, including cancer. CDKN2D is a variant of the p16INK4a gene that has been shown to have altered functional characteristics compared to the wild-type gene.

One of the key differences between CDKN2D and the wild-type gene is the presence of a missense mutation at position 224. This mutation has been shown to alter the stability and localization of the p16INK4a protein. The missense mutation has been shown to affect the stability and localization of the protein, leading to changes in its function.

In cancer cells, the expression of CDKN2D is often increased compared to the wild-type gene. This increased expression of CDKN2D has been shown to promote the growth and survival of cancer cells. The altered function of CDKN2D has led to the development of various diseases, including cancer.

CDKN2D as a Biomarker:

CDKN2D has also been shown to serve as a biomarker for cancer. The altered expression of CDKN2D has been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer therapies.

CDKN2D has been shown to be involved in various signaling pathways, including the NF-kappa pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of cancer.

In addition to its involvement in the NF-kappa pathway, CDKN2D has also been shown to be involved in the PI3K/AKT pathway. This pathway is involved in cell signaling and is also involved in the development and progression of cancer.

CDKN2D as a Potential Drug Target:

The potential drug targets for CDKN2D include inhibiting the activity of the p16INK4a protein, as well as inhibiting the function of CDKN2D itself.

One approach to inhibiting the activity of the p16INK4a protein is through the use of small molecules. Small molecules have been shown to be effective in inhibiting the activity of various proteins, including the p16INK4a protein. These small molecules can be used to treat various diseases, including cancer.

Another approach to inhibiting the function of CDKN2D is through the use of drugs that target the PI3K/AKT pathway. The PI3K/AKT pathway is

Protein Name: Cyclin Dependent Kinase Inhibitor 2D

Functions: Interacts strongly with CDK4 and CDK6 and inhibits them

The "CDKN2D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKN2D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets